Replies to post #19489 on Synaptogenix Inc (SNPX)

[Cyosol]

Topline data is this year but full data won't be out until next year.

They have enough cash to survive until 2024 but that doesn't include additional trials, which they need for approval.

The cash they have needs to be spent on getting a drug approved so they can start earning revenues and stop diluting their stock.